{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:11:38Z","timestamp":1790014298417,"version":"4.0.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T00:00:00Z","timestamp":1735603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T00:00:00Z","timestamp":1735603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["PR-PRU-1217-20401"],"award-info":[{"award-number":["PR-PRU-1217-20401"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["PR-PRU-1217-20401"],"award-info":[{"award-number":["PR-PRU-1217-20401"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s40273-024-01450-3","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T07:16:54Z","timestamp":1735629414000},"page":"363-373","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["A Framework for Using Cost-effectiveness Analysis to Support Pricing and Reimbursement Decisions for New Pharmaceuticals in a Context of Evolving Treatments, Prices, and Evidence"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7669-9415","authenticated-orcid":false,"given":"Beth","family":"Woods","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7684-0880","authenticated-orcid":false,"given":"Alfredo","family":"Palacios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3746-9913","authenticated-orcid":false,"given":"Mark","family":"Sculpher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,31]]},"reference":[{"issue":"1","key":"1450_CR1","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jval.2013.10.008","volume":"17","author":"L Barnieh","year":"2014","unstructured":"Barnieh L, Manns B, Harris A, Blom M, Donaldson C, Klarenbach S, et al. A synthesis of drug reimbursement decision-making processes in organisation for economic co-operation and development countries. Value Health. 2014;17(1):98\u2013108.","journal-title":"Value Health."},{"issue":"3","key":"1450_CR2","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s40258-023-00867-9","volume":"22","author":"N Zozaya","year":"2024","unstructured":"Zozaya N, Villaseca J, Fernandez I, Abdalla F, Cadenas-Norena B, Calleja MA, et al. A review of current approaches to evaluating and reimbursing new medicines in a subset of OECD countries. Appl Health Econ Health Policy. 2024;22(3):297\u2013313.","journal-title":"Appl Health Econ Health Policy"},{"key":"1450_CR3","volume-title":"2024 Voluntary Scheme for Branded Medicines Pricing","author":"Department of Health and Social Care","year":"2024","unstructured":"Department of Health and Social Care. 2024 Voluntary Scheme for Branded Medicines Pricing. London: Access and Growth; 2024."},{"key":"1450_CR4","volume-title":"NICE health technology evaluations: the manual","author":"National Institute for Health and Care Excellence","year":"2022","unstructured":"National Institute for Health and Care Excellence. NICE health technology evaluations: the manual. London: NICE; 2022."},{"key":"1450_CR5","unstructured":"Perelman J, Soares M, Mateus C, Duarte A, Faria R, Ferreira L, et al. Methodological guidelines for economic evaluation studies. INFARMED\u2013National Authority of Medicines and Health Products. Lisbon: IP; 2019. https:\/\/www.infarmed.pt\/documents\/15786\/4001413\/Orienta\u00e7\u00f5es+metodol\u00f3gicas+para+estudos+de+avalia\u00e7\u00e3o+econ\u00f3mica+de+tecnologias+de+sa\u00fade+%28EN%29\/ebcfd930-94e2-c7e1-100a-ee1df3d76882. Accessed 14 Nov 2024."},{"key":"1450_CR6","unstructured":"Australian Government: Department of Health and Aged Care. Post-market reviews of Pharmaceutical Benefits Scheme subsidised medicines 2024. Available from: https:\/\/www.pbs.gov.au\/info\/reviews\/subsidised-medicines-reviews. Accessed 10 Oct 2024."},{"key":"1450_CR7","unstructured":"Tandv\u00e5rds- och l\u00e4kemedelsf\u00f6rm\u00e5nsverket T. TLV genomf\u00f6r och f\u00f6resl\u00e5r nya \u00e5tg\u00e4rder f\u00f6r \u00f6kad prisdynamik p\u00e5 l\u00e4kemedelsmarknaden 2022. Available from: https:\/\/www.tlv.se\/press\/nyheter\/arkiv\/2022-06-16-tlv-genomfor-och-foreslar-nya-atgarder-for-okad-prisdynamik-pa-lakemedelsmarknaden.html?query=%20v%C3%A4rdebaserad%20priss%C3%A4ttning. Accessed 10 Oct 2024."},{"issue":"5","key":"1450_CR8","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s41669-024-00490-x","volume":"8","author":"D Lee","year":"2024","unstructured":"Lee D, Burns D, Wilson E. NICE\u2019s pathways pilot: pursuing good decision making in difficult circumstances. Pharmacoecon Open. 2024;8(5):645\u20139.","journal-title":"Pharmacoecon Open."},{"key":"1450_CR9","unstructured":"National Institute for Health and Care Excellence. Interim methods and processes statement for including NICE technology appraisal recommendations in guideline topic areas. London: NICE; 2024. Available from: https:\/\/www.nice.org.uk\/consultations\/2495\/8\/integrating-nice-technology-appraisal-recommendations. Accessed 14 Nov 2024."},{"key":"1450_CR10","unstructured":"Canadian Drug and Health Technology Agency. Pilot expert committee to support decision-making across the drug life cycle 2023. Available from: https:\/\/www.cadth.ca\/news\/pilot-expert-committee-support-decision-making-across-drug-life-cycle. Accessed 13 Feb 2024."},{"key":"1450_CR11","doi-asserted-by":"publisher","first-page":"1234414","DOI":"10.3389\/fphar.2023.1234414","volume":"14","author":"S Cheyne","year":"2023","unstructured":"Cheyne S, Chakraborty S, Lewis S, Campbell S, Turner T, Norris S. What could health technology assessment learn from living clinical practice guidelines? Front Pharmacol. 2023;14:1234414.","journal-title":"Front Pharmacol"},{"key":"1450_CR12","first-page":"194","volume":"7","author":"R Smith","year":"2022","unstructured":"Smith R, Schneider P, Mohammed W. Living HTA: automating health economic evaluation with R [version 2; peer review: 2 approved]. Wellcome Open Res. 2022;7:194.","journal-title":"Wellcome Open Res."},{"issue":"3","key":"1450_CR13","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s40273-022-01229-4","volume":"41","author":"P Thokala","year":"2023","unstructured":"Thokala P, Srivastava T, Smith R, Ren S, Whittington MD, Elvidge J, et al. Living health technology assessment: issues, challenges and opportunities. Pharmacoeconomics. 2023;41(3):227\u201337.","journal-title":"Pharmacoeconomics"},{"key":"1450_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1700","author":"AE Ades","year":"2024","unstructured":"Ades AE, Welton NJ, Dias S, Phillippo DM, Caldwell DM. Twenty years of network meta-analysis: Continuing controversies and recent developments. Res Synth Methods. 2024. https:\/\/doi.org\/10.1002\/jrsm.1700.","journal-title":"Res Synth Methods."},{"issue":"4","key":"1450_CR15","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1002\/hec.4795","volume":"33","author":"B Woods","year":"2024","unstructured":"Woods B, Lomas J, Sculpher M, Weatherly H, Claxton K. Achieving dynamic efficiency in pharmaceutical innovation: Identifying the optimal share of value and payments required. Health Econ. 2024;33(4):804\u201319.","journal-title":"Health Econ"},{"issue":"Suppl 1","key":"1450_CR16","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1017\/bca.2018.29","volume":"10","author":"K Claxton","year":"2019","unstructured":"Claxton K, Asaria M, Chansa C, Jamison J, Lomas J, Ochalek J, et al. Accounting for timing when assessing health-related policies. J Benefit Cost Anal. 2019;10(Suppl 1):73\u2013105.","journal-title":"J Benefit Cost Anal."},{"key":"1450_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.100887","volume":"40","author":"B Mihaylova","year":"2024","unstructured":"Mihaylova B, Wu R, Zhou J, Williams C, Schlackow I, Emberson J, et al. Lifetime effects and cost-effectiveness of standard and higher-intensity statin therapy across population categories in the UK: a microsimulation modelling study. Lancet Reg Health Eur. 2024;40: 100887.","journal-title":"Lancet Reg Health Eur."},{"issue":"5","key":"1450_CR18","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.jval.2019.03.006","volume":"22","author":"J Love-Koh","year":"2019","unstructured":"Love-Koh J, Cookson R, Gutacker N, Patton T, Griffin S. Aggregate distributional cost-effectiveness analysis of health technologies. Value Health. 2019;22(5):518\u201326.","journal-title":"Value Health."},{"issue":"2","key":"1450_CR19","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1002\/hec.3561","volume":"27","author":"KM Johannesen","year":"2018","unstructured":"Johannesen KM, Claxton K, Sculpher MJ, Wailoo AJ. How to design the cost-effectiveness appraisal process of new healthcare technologies to maximise population health: A conceptual framework. Health Econ. 2018;27(2):e41\u201354.","journal-title":"Health Econ"},{"issue":"7","key":"1450_CR20","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.jval.2021.11.1373","volume":"25","author":"E Kirwin","year":"2022","unstructured":"Kirwin E, Round J, Bond K, McCabe C. A conceptual framework for life-cycle health technology assessment. Value Health. 2022;25(7):1116\u201323.","journal-title":"Value Health."},{"key":"1450_CR21","unstructured":"National Centre for Pharmacoeconomics. 2022. Cost-effectiveness of ravulizumab (Ultomiris\u00ae) for the treatment of patients weighing at least 10kg with atypical haemolytic uraemic syndrome (aHUS), who are complement inhibitor treatment-na\u00efve or have received eculizumab for at least three months and have evidence of response to eculizumab. https:\/\/ncpe.ie\/wpcontent\/uploads\/2020\/08\/Ravulizumab-for-aHUS-Technical-Summary-20036-Final-updatedWebsite.pdf. Accessed 18 Oct 2024."},{"key":"1450_CR22","volume-title":"Bortezomib and thalidomide for the first-line treatment of multiple myeloma","author":"National Institute for Health and Care Excellence","year":"2011","unstructured":"National Institute for Health and Care Excellence. Bortezomib and thalidomide for the first-line treatment of multiple myeloma. London: NICE; 2011."},{"key":"1450_CR23","volume-title":"Lenalidomide plus dexamethasone for previously untreated multiple myeloma","author":"National Institute for Health and Care Excellence","year":"2019","unstructured":"National Institute for Health and Care Excellence. Lenalidomide plus dexamethasone for previously untreated multiple myeloma. London: NICE; 2019."},{"issue":"9","key":"1450_CR24","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2165\/00019053-200826090-00009","volume":"26","author":"M Sculpher","year":"2008","unstructured":"Sculpher M. Subgroups and heterogeneity in cost-effectiveness analysis. Pharmacoeconomics. 2008;26(9):799\u2013806.","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"1450_CR25","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.jhealeco.2011.03.004","volume":"30","author":"A Basu","year":"2011","unstructured":"Basu A. Economics of individualization in comparative effectiveness research and a basis for a patient-centered health care. J Health Econ. 2011;30(3):549\u201359.","journal-title":"J Health Econ"},{"key":"1450_CR26","doi-asserted-by":"crossref","unstructured":"Basu A, Jena AB, Goldman DP, Philipson TJ, Dubois R. Heterogeneity in action: The role of passive personalization in comparative effectiveness research. Health Econ. 2014;23(3):549\u201359.","DOI":"10.1002\/hec.2996"},{"issue":"2","key":"1450_CR27","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1177\/0272989X06297393","volume":"27","author":"A Basu","year":"2007","unstructured":"Basu A, Meltzer D. Value of information on preference heterogeneity and individualized care. Med Decis Making. 2007;27(2):112\u201327.","journal-title":"Med Decis Making"},{"issue":"2","key":"1450_CR28","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1002\/hec.3559","volume":"27","author":"MA Espinoza","year":"2018","unstructured":"Espinoza MA, Manca A, Claxton K, Sculpher M. Social value and individual choice: The value of a choice-based decision-making process in a collectively funded health system. Health Econ. 2018;27(2):e28\u201340.","journal-title":"Health Econ"},{"issue":"2","key":"1450_CR29","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/(SICI)1099-1050(199803)7:2<129::AID-HEC332>3.0.CO;2-9","volume":"7","author":"M Sculpher","year":"1998","unstructured":"Sculpher M. The cost-effectiveness of preference-based treatment allocation: the case of hysterectomy versus endometrial resection in the treatment of menorrhagia. Health Econ. 1998;7(2):129\u201342.","journal-title":"Health Econ"},{"issue":"13","key":"1450_CR30","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1001\/jama.1990.03450130109039","volume":"264","author":"DM Eddy","year":"1990","unstructured":"Eddy DM. Clinical decision making: from theory to practice. Connecting value and costs Whom do we ask, and what do we ask them? JAMA. 1990;264(13):1737\u20139.","journal-title":"JAMA"},{"issue":"4","key":"1450_CR31","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.jval.2023.12.013","volume":"27","author":"B Jiao","year":"2024","unstructured":"Jiao B, Carlson JJ, Garrison LP Jr, Basu A. Evaluating policies of expanding versus restricting first-line treatment choices: a cost-effectiveness analysis framework. Value Health. 2024;27(4):433\u201340.","journal-title":"Value Health."},{"key":"1450_CR32","doi-asserted-by":"publisher","unstructured":"Barrenho E, Moens M, Waagstein L, Lopert R. Enhancing competition in on-patent markets.In: OECD Health Working Papers, No. 156. Paris: OECD Publishing; 2023. https:\/\/doi.org\/10.1787\/413f2820-en.","DOI":"10.1787\/413f2820-en"},{"key":"1450_CR33","unstructured":"Kettler H. Competition through innovation, innovation through competition. London; 1998."},{"issue":"8","key":"1450_CR34","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s40273-020-00914-6","volume":"38","author":"M Paulden","year":"2020","unstructured":"Paulden M. Calculating and Interpreting ICERs and net benefit. Pharmacoeconomics. 2020;38(8):785\u2013807.","journal-title":"Pharmacoeconomics"},{"issue":"8","key":"1450_CR35","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s40273-020-00915-5","volume":"38","author":"M Paulden","year":"2020","unstructured":"Paulden M. Why it\u2019s time to abandon the ICER. Pharmacoeconomics. 2020;38(8):781\u20134.","journal-title":"Pharmacoeconomics"},{"issue":"11","key":"1450_CR36","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1002\/hec.4393","volume":"30","author":"B Woods","year":"2021","unstructured":"Woods B, Fox A, Sculpher M, Claxton K. Estimating the shares of the value of branded pharmaceuticals accruing to manufacturers and to patients served by health systems. Health Econ. 2021;30(11):2649\u201366.","journal-title":"Health Econ"},{"issue":"9","key":"1450_CR37","doi-asserted-by":"publisher","first-page":"781","DOI":"10.2165\/00019053-200826090-00008","volume":"26","author":"K Claxton","year":"2008","unstructured":"Claxton K. Exploring uncertainty in cost-effectiveness analysis. Pharmacoeconomics. 2008;26(9):781\u201398.","journal-title":"Pharmacoeconomics"},{"issue":"14","key":"1450_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta19140","volume":"19","author":"K Claxton","year":"2015","unstructured":"Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S, et al. Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. Health Technol Assess. 2015;19(14):1\u2013503 (v-vi).","journal-title":"Health Technol Assess"},{"issue":"5","key":"1450_CR39","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jval.2016.02.020","volume":"19","author":"L Vallejo-Torres","year":"2016","unstructured":"Vallejo-Torres L, Garcia-Lorenzo B, Castilla I, Valcarcel-Nazco C, Garcia-Perez L, Linertova R, et al. On the estimation of the cost-effectiveness threshold: why, what, how? Value Health. 2016;19(5):558\u201366.","journal-title":"Value Health."},{"issue":"9","key":"1450_CR40","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.jval.2019.04.1926","volume":"22","author":"J Lomas","year":"2019","unstructured":"Lomas J, Martin S, Claxton K. Estimating the marginal productivity of the English national health service from 2003 to 2012. Value Health. 2019;22(9):995\u20131002.","journal-title":"Value Health."},{"key":"1450_CR41","volume-title":"Statutory scheme to control costs of branded health service medicines","author":"Department of Health and Social Care","year":"2020","unstructured":"Department of Health and Social Care. Statutory scheme to control costs of branded health service medicines. London: Department of Health and Social care; 2020."},{"key":"1450_CR42","unstructured":"Dixon S. Including patient choice in cost-effectiveness decision rules. Sheffield:University of Sheffield; 2007. https:\/\/eprints.whiterose.ac.uk\/10913\/1\/HEDS_DP_07-06.pdf. Accessed 14 Nov 2024."},{"key":"1450_CR43","unstructured":"Specialist Pharmacy Service. \u201cTranche\u201d branded medicines in a competitive market. 2021. Available from: https:\/\/www.sps.nhs.uk\/articles\/tranche-branded-medicines-in-a-competitive-market\/. Accessed 13 Nov 2024."},{"key":"1450_CR44","unstructured":"National Institute for Health and Care Excellence. NICE-wide topic prioritisation: the manual. London: NICE; 2024. Available from: https:\/\/www.nice.org.uk\/process\/pmg46. Accessed 18 June 2024."},{"key":"1450_CR45","doi-asserted-by":"publisher","unstructured":"Neumann PJ, Cohen JT. Are we valuing prescription drugs appropriately? Health Aff Forefront. 2024. https:\/\/doi.org\/10.1377\/forefront.20240130.833652","DOI":"10.1377\/forefront.20240130.833652"},{"issue":"1","key":"1450_CR46","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jval.2021.06.014","volume":"25","author":"PJ Neumann","year":"2022","unstructured":"Neumann PJ, Podolsky MI, Basu A, Ollendorf DA, Cohen JT. Do cost-effectiveness analyses account for drug genericization? A literature review and assessment of implications. Value Health. 2022;25(1):59\u201368.","journal-title":"Value Health."},{"issue":"7","key":"1450_CR47","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jval.2024.03.006","volume":"27","author":"M Puls","year":"2024","unstructured":"Puls M, Horscroft J, Kearns B, Gladwell D, Church E, Johannesen K, et al. Challenges of incorporating life cycle drug pricing in cost-effectiveness models: a review of methods and modeling suggestions. Value Health. 2024;27(7):978\u201385.","journal-title":"Value Health."},{"key":"1450_CR48","volume-title":"Board meeting 17th July 2024: including NICE technology appraisal guidance in guidelines","author":"National Institute for Health and Care Excellence","year":"2024","unstructured":"National Institute for Health and Care Excellence. Board meeting 17th July 2024: including NICE technology appraisal guidance in guidelines. London: NICE; 2024."}],"updated-by":[{"DOI":"10.1007\/s40273-025-01513-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000}}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-024-01450-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-024-01450-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-024-01450-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T06:04:19Z","timestamp":1751695459000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-024-01450-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,31]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1450"],"URL":"https:\/\/doi.org\/10.1007\/s40273-024-01450-3","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,31]]},"assertion":[{"value":"22 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2025","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised due to retrospective open access.","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2025","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40273-025-01513-z","URL":"https:\/\/doi.org\/10.1007\/s40273-025-01513-z","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Beth Woods sits on the Board of Directors for the York Health Economics Consortium, a health economics consultancy company wholly owned by the University of York. This is an unpaid role. Alfredo Palacios and Mark Sculpher have no competing interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"This research was funded by the National Institute for Health and Care Research (NIHR) Policy Research Programme, conducted through the Policy Research Unit in Economic Methods of Evaluation in Health and Social Care Interventions, PR-PRU-1217-20401. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care or its arm's-length bodies, or other UK government departments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"No data were used in the conduct of this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"BW and MS conceived of the study and conducted the workshop. AP and BW conducted the literature review, and all authors conducted the synthesis of information and development of the framework. BW wrote the initial draft of the manuscript, which was then critically reviewed by all authors.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors Contributions"}}]}}